Navigation Links
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
Date:7/11/2011

WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm® technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR"), announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.  The Company made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical, Inc. (NYSE: PRX), who had been marketing the product as part of an exclusive licensing agreement since its commercial launch in October 2010.  The New Drug Application (NDA) for Zuplenz will remain current and commercial availability will not be disrupted.

Zuplenz is a unique film formulation delivering either 4 or 8 mgs of ondansetron and was developed using MonoSol Rx's proprietary PharmFilm technology.  It is indicated for the prevention of postoperative nausea and vomiting (PONV), highly and moderately emetogenic cancer chemotherapy-induced nausea and vomiting (CINV), and radiotherapy-induced nausea and vomiting (RINV).  Zuplenz is poised to capture a broad share of this market, which generated $1.9 billion in 2010.

"Zuplenz provides patients suffering from nausea and vomiting as a result of chemotherapy or surgery with a minimally invasive and highly tolerable drug delivery form," said A. Mark Schobel, Chief Technology Officer and CEO, MonoSol Rx.  "We believe Zuplenz has the potential to improve the quality of life for many cancer patients in need of better supportive care and offers an important new dosage form for improving postoperative care for both inpatient and outpatient surgeries.  We look forward to maximizing this potential with a pharmaceutical partner that can effectively detail t
'/>"/>

SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
2. MonoSol Rx Issued Strategic US Patent Governing the Production of Pharmaceutical Films Containing Specific Drugs and Drug Classes
3. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
4. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
5. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
6. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
7. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
10. Stryker Announces Exclusive Collaboration With RegenLab
11. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... und MARSEILLE , Frankreich, ... , Weltweite Exklusivlizenz der Universität ... die Entwicklung von Tests auf SF3B1-Mutationen, einschließlich ... Neuer Test weist Mutationen des SF3B1-Gens ... Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NasdaqGS: ABAX ), a medical products ... results for the first fiscal quarter ended June 30, ... of $47.5 million, up 10% over last year,s comparable ... over last year,s comparable quarter. Revenues highlights: ... 20% over last year,s comparable quarter. , Veterinary ...
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... The report, “Glass Fiber & Glass Fiber Reinforced ... Manufacturing Process, By Application (Transportation, Construction, Electrical & ... Trends & Forecast to 2019”, defines and segments ... and forecast by value and volume. , Browse ... through 347 slides and in-depth TOC on "GFRP ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... TUCSON, Ariz., Nov. 25 ... announced that its LogistiCare subsidiary, the nation,s largest coordinator ... award from the State of Florida Commission for the ... both Miami-Dade and Volusia Counties. The award, estimated ...
... , - Agreement Provides Financial Flexibility, Allowing ... Quebec, Nov. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... standby equity distribution agreement (SEDA) with YA Global Master SPV ... terms of the agreement, YA has committed to provide up ...
... and other greenhouse emissions will have major direct health ... change, especially in low-income countries, according to a series ... the British journal The Lancet . Two ... Kirk R. Smith, professor of global environmental health, and ...
... ... sinusitis. A clinically proven, minimally invasive technology for treating chronic sinus inflammation is available ... a small catheter and balloon to quickly open and expand blocked sinuses. , ... (Vocus) November 25, 2009 ...
... ... be offering $100 off every memory foam and latex sofa bed mattress + an additional ... code “BLACKFRIDAY” in the shopping cart to take advantage of this special offer. , ... (PRWEB) November 25, 2009 -- Millions ...
... ... your Emergency Department,s management of seasonal and pandemic novel H1N1 influenza cases this season? ... Which - if any - antiviral should you prescribe? EB Medicine announces its November ... resources on influenza diagnosis and treatment. , ...
Cached Medicine News:Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 2Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 3
... first manufacturer to offer through-the-lens (TTL) ... These next generation loupes feature extremely ... design, and are multi-coated lens for ... SheerVision's proprietary SureFit system - you ...
Easy pull-on garment's feature Rainey's exclusive Non-Slip Dome™design and adjustable Velcro© closure at neck for optimal comfort and support. Choose covered or non covered ear design....
Facial Wrap...
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Medicine Products: